Last Updated on December 24, 2023 by The Health Master
Zydus Lifesciences has received final approval from the US Food and Drug Administration (USFDA) to market Empagliflozin Tablets USP 10 mg and 25 mg, a company statement announced.
It is said that the tablet is used to lower blood sugar levels in people with type-II diabetes.
It is also used to reduce the risk of stroke, heart attack, or death in people with type-II diabetes, along with heart and blood vessel disease.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ.
USFDA gives final approval to market this anti-inflammatory skin cream
USFDA grants approval for generic Cyclosporine Soft Gel capsules
USFDA gives nod for Diclofenac Sodium Topical Gel
USFDA gives nod for generic birth control pills
USFDA gives nod for Belimumab to treat Paediatric Patients
USFDA gives nod for this generic high Blood Pressure drug
FDA Haryana busted a fake medicine factory
USFDA issues Form 483 for 6 observations to Jubilant Pharmova
USFDA gives final approval to market this anti-inflammatory skin cream
FDA Maharashtra seizes diagnostic kits being sold without license
9th edition of Indian Pharmacopoeia released: Details
Govt is set to ban Codeine-based Cough Syrups and formulations
NPPA extends timeline for trade margin capping of these 5 Medical Devices
Govt releases new National Standards for Blood Centres and Blood Transfusion
Drug prices: What is One-molecule, One-price policy ?
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
